Depression may also be associated with increased mortality Unfo

Depression may also be associated with increased mortality. Unfortunately, this treatable cause of suffering is frequently misdiagnosed and poorly treated in patients with cancer who are dying. In addition to traditional psychosocial and pharmacological treatments, several novel approaches to end-of-life care have been shown to result in robust improvement in depressive symptoms for patients with terminal cancer. These comprehensive and patient-centered

interventions offer patients the incalculable benefits of less suffering and optimum communication with family, friends, and clinicians providing care for them at the end of life.
Major Inhibitors,research,lifescience,medical depressive disorder (MDD), one of the most common psychiatric illnesses in the adult Inhibitors,research,lifescience,medical population, is a major cause of disability1 and is associated with a twofold increase in nonsuicidal mortality in women.2 In addition to poor kinase inhibitor Cisplatin Medical compliance and lifestyle factors, endocrine, immune, and autonomic dysregulations may play a causative role in producing medical illnesses Inhibitors,research,lifescience,medical in patients with MDD.3,4 The goal of this article is to describe some of the most clinically relevant medical consequences of major depression by summarizing here the findings of the POWER (Premenopausal, Osteoporosis Women, Alendronate, Depression) Study. The medical consequences of depression, as observed in the POWER Study, included

osteoporosis, endocrine and immune alterations, subclinical inflammation and alterations in coagulability, Inhibitors,research,lifescience,medical chronic pain, and decreased quality of life. Some of the novel pathogenetic mechanisms unraveled will be discussed. This review will conclude by listing some implications for clinical practice and future research. Medical consequences of major depression in premenopausal mildly depressed women mostly in remission The POWER study Women with MDD

were likewise characterized with a matched Inhibitors,research,lifescience,medical group of healthy women from an immune, endocrine, and inflammatory point of view and prospectively followed for 36 months, with evaluations at baseline, 6, 12, 24, and 36 months.5 In the POWER Study, the presence of a control group prevented artifacts secondary to a nonspecific “study effect” on mood and provided Carfilzomib a benchmark for the research measurements taken. Study design The POWER Study was a three-year prospective investigation of bone turnover and other measurements conducted at the NIH Clinical Center.5 Recruitment was conducted from July 2001 to February 2003 in the Washington, DC, metropolitan area by advertising in newspapers, radio, flyers and on the Internet. We enrolled 89 communitydwelling 21- to 45-year-old premenopausal women with current or recent MDD and 44 healthy control women. Women were enrolled if they met DSM-IV criteria for MDD, and had experienced a depressive episode in the preceding three years.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>